ESMO 2024 | BOVARY-pilot: expanding the role of liquid biopsy in diagnostics and MRD detection

Alexandre Harlé • 14 Sep 2024

ESMO 2024

BOVARY-pilot

Alexandre Harlé, PharmD, PhD, Université de Lorraine, Nancy, France, highlights the growing potential of liquid biopsy as a less invasive alternative to tissue biopsy. He emphasizes its use in both diagnostics and monitoring minimal residual disease (MRD). In the BOVARY-pilot trial (NCT03881683), liquid biopsy was employed to detect key cancer features at baseline and then to track patients for MRD, aiming to predict and potentially prevent relapse. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.